



SHUKRA

PHARMACEUTICALS LTD.

August 14, 2026

To,
The Listing Compliance Department
BSE Limited
P. J. Towers, Dalal Street
Mumbai – 400001
Scrip Code: 524632

To,
The Listing Department
National Stock Exchange of India
Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051
Symbol: SHUKRAPHAR

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Execution of Term Sheet for proposed Strategic Joint Venture with Borns Medical Robotics

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the Stock Exchanges that Shukra Pharmaceuticals Limited ("Shukra" / "the Company") has entered into a Term Sheet with Borns Medical Robotics Pte Ltd, Singapore ("Borns"), for establishing a strategic joint venture for the design, manufacture, distribution and servicing of AI-enabled surgical robotic systems in India and the Asia-Pacific region.

The key particulars of the Term Sheet are set out below:

Particulars	Details
Name(s) of the parties with whom the agreement is entered into	Shukra Pharmaceuticals Limited and Borns Medical Robotics Pte Ltd / proposed Singapore-incorporated holding entity of Borns Medical Robotics
Purpose of entering into the agreement	To establish a strategic joint venture for designing, manufacturing, distributing and servicing AI-enabled surgical robotic systems in India and the Asia-Pacific region alongwith un-regulated market. After completion of USFDA/CE certificate, entered into the rest of the world.
Nature of agreement	Strategic Joint Venture Term Sheet / Heads of Terms setting out the principal commercial and legal framework for the proposed joint venture and the definitive agreements to be executed between the parties.
Date of execution	August 13, 2026 CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

Particulars	Details
Tenure / duration of the agreement	The Term Sheet contemplates implementation through definitive agreements. The proposed joint venture is intended to continue subject to the terms of the definitive agreements.
Shareholding / ownership structure proposed	Shukra – 60% and Borns Singapore – 40% in the proposed Indian joint venture entity, B&S Robotics Private Limited.
Name of proposed JV entity	B&S Robotics Private Limited ("B&S India"), India.
Nature of business of JV	Design, manufacture, distribution and servicing of AI-enabled surgical robotic systems, together with related instruments, consumables, software and services, within the approved field of use and territory.
Contribution by Shukra	Shukra proposes to contribute capital and provide its sales and distribution network, skilled team, market-development capabilities, branding support, infrastructure initiatives and financing ecosystem.
Contribution by Borns	Borns proposes to contribute its technology platform and surgical robotic systems, together with relevant technology/IP support, manufacturing know-how and related technical capabilities, in accordance with the definitive agreements.
Initial capital / consideration	The initial paid-up capital of B&S India is yet to be determined under the definitive agreements. Subscription is proposed in the ratio of 60:40.
Whether the transaction falls within related party transaction	Based on the information presently available, the proposed transaction is not a related party transaction. The Company shall comply with applicable related party transaction requirements, if and when applicable.
Material terms	The Term Sheet contemplates, inter alia, incorporation of B&S India, incorporation of B&S Singapore Pte. Ltd., investment by Borns Singapore, IP licensing arrangements, transitional supply and distribution arrangements, technology transfer/localisation, governance, royalty arrangements, territory and exclusivity, financing, regulatory responsibilities and a potential future demerger/listing pathway.

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

Particulars	Details
Governance	The proposed Board of B&S India is contemplated to comprise five directors, of whom three shall be nominated by Shukra and two by Borna Singapore, with governance arrangements to be further documented in the Shareholders' Agreement and Articles of Association.
Exclusivity	The Term Sheet contains binding exclusivity provisions in relation to the surgical robotics category covering the Primary Territory, subject to the terms set out therein.
Definitive agreements	The parties intend to enter into definitive agreements including the Shareholders' Agreement, Articles of Association, Master IP Licensing Agreement, Sub-License and Royalty Agreement, Transitional Supply & Distribution Agreement, Subscription Agreement, Quality Agreement, Data Processing/AI Use and Cybersecurity Agreement and other ancillary agreements.
Conditions precedent	The proposed transaction is subject to, inter alia, establishment of the Borna Singapore entity, completion of mutual due diligence, independent valuation, applicable regulatory/FEMA/FDI confirmations, necessary corporate approvals, IP due diligence, regulatory pathway confirmation, execution of definitive agreements and other conditions precedent specified in the Term Sheet.
Regulatory approvals	Applicable regulatory and statutory approvals/filings, including FEMA/FDI-related compliances, CDSCO and other applicable regulatory approvals, and other approvals as may be required, shall be obtained/complied with in accordance with applicable law.
Expected timeline	The parties have contemplated incorporation of the JV entities and execution of the definitive agreements, with the Long Form Agreements targeted within approximately 120 days from execution of the Term Sheet, subject to satisfaction of the applicable conditions precedent.
Impact on financial position	The Term Sheet itself does not specify any fixed immediate financial commitment or final investment amount by the Company. The financial impact, if any, shall be determined upon execution of the definitive agreements and completion of the proposed investment/subscription.

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

Particulars	Details
Whether the agreement is in the ordinary course of business	The proposed strategic joint venture is not in the ordinary course of business of the Company and is therefore being disclosed pursuant to the applicable provisions of Regulation 30 and Schedule III of the LODR Regulations.
Termination / binding nature	Except for specified provisions relating to confidentiality, exclusivity, costs, governing law and jurisdiction, the Term Sheet is stated to be non-binding and does not by itself create a contractual obligation to complete the proposed transaction. The definitive rights and obligations of the parties shall be governed by the Long Form Agreements.

The proposed joint venture is intended to create a platform for development of the surgical robotics business in India, progressive localisation of manufacturing and expansion into the APAC region. The Term Sheet contemplates that, subject to achievement of agreed milestones and applicable regulatory approvals, the parties may pursue a future demerger and listing of the joint venture entity on BSE and NSE. The proposed listing is stated to be a strategic objective and is not a guaranteed exit or listing commitment.


The Company will make further disclosures to the Stock Exchanges as and when the definitive agreements are executed and/or upon occurrence of any material development in accordance with Regulation 30 and other applicable provisions of the LODR Regulations. The above information is also being made available on the Company's website.

You are requested to kindly take the same on record.

Thanking you,

For Shukra Pharmaceuticals Limited

Name: Shivkant Dhakad
Designation: Company Secretary
Membership No.: A80894



CIN : L24231GJ1993PLC019079